632 results about "Cancer cell proliferation" patented technology

The invention relates to antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D)p  I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the multiplication of a tumor cell or cancer cell including administering to a patient an effective amount of a Formula I ADC.

The invention relates to bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D)p   I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked, through the wavy line, by a linker (L) to an antibody (Ab). The invention also relates to heterocyclic-substituted 1,8 bis-naphthalimide compounds having Formula XV The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC or Formula XV heterocyclic-substituted 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a Formula I ADC or Formula XV compound.

Synthetic peptides containing an ankyrin repeat-like motif or portion thereof and mimetics thereof which interact with synuclein-gamma (SNCG) and reduce SNCG-mediated resistance of SNCG-expressing cancer cells to treatment with anticancer drugs or inhibit tumorigenesis and cancer cell proliferation are provided. Compositions containing these peptides, portions thereof or mimetics thereof are also provided. Methods for use of these peptides or portions thereof, compositions, and mimetics thereof in potentiating efficacy of anticancer drugs, in particular microtubule inhibitors and hormonal cancer therapies, and in treating cancer are also provided.

The present invention provides oral dosage forms and compositions for administering antineoplastic agents, such as irinotecan, etoposide, paclitaxel, doxorubicin and vincristine, whose oral effectiveness is limited by pre-systemic and systemic deactivation in the GI tract. Gelling of the gastric retention vehicle composition, and in the case of solid forms concomitant expansion of the composition, retains the antineoplastic drug in the patient's stomach, minimizing pre-systemic and / or systemic deactivation of the drug.

Bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) are described. Pharmaceutical compositions comprising an effective amount of a 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders are described. Methods are described for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a 1,8 bis-naphthalimide compound.

A material for suppressing proliferation of cancer cells is produced by entrapping cancer cells in a selectively-permeable structure such as a bead, and culturing the entrapped cells in a culture medium. Entrapment restricts growth of the cancel cells during culturing and causes the cells to produce in the culture medium a material having a molecular weight of at least about 30 kd as measured by filtration that suppresses proliferation of cancer cells. The material is separated from the culture medium by filtering the medium through a filter that separates material having a molecular weight of at least about 30 kd from material having a molecular weight of less than 30 kd. The structure that entraps the cells may contain 10,000 to 500,000 cells. The material or the structure containing the entrapped cells that produce the material can be administered to a subject to suppress cancer cell proliferation.

Medicinal compositions which are useful as phosphatidylinositol 3-kinase (PI3K) inhibitors and anticancer agents; and novel bicyclic or tricyclic condensed heteroaryl derivatives or salts thereof having favorable effects of inhibiting PI3K and suppressing the proliferation of cancer cells.

The present invention provides for pharmaceutical compositions comprising carvedilol for treatment of cancer. More particularly the invention relates to the use of carvedilol for treatment of cancers of the colon, ovary, breast, prostate, pancreas, lung, melanoma, glioblastoma, oral cancer and leukemias. Although not bound to any theory, the anticancer activity of carvedilol appears to be attributed to the inhibition of Epidermal Growth Factor and Platelet derived growth factor dependent proliferation of cancer cells. Further, carvedilol exerts anticancer effect by inhibition of the Protein kinase C (PKC) activity and that of the cyclooxygenase 2 enzyme. The invention also relates to the anticancer activity of the optically pure isomers S(-) and R(+) of carvedilol and the use of carvedilol and its isomers in pharmaceutical compositions for the treatment of cancer.< / PTEXT>

The invention is of both a composition and method for inhibiting the proliferation of cancerous cells. The composition is, and the method is based on the use of a composition consisting (among active ingredients) substantially of 2-methoxyestradiol and / or one of a number of anaologues thereof. The present inventors have demonstrated beyond serious doubt that these compounds have a pronounced effect in inhibiting the proliferation of cancerous cells and, therefore, provide a desperately needed stepping stone for advancing toward meaningful treatment of cancer.

A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and / or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells.

Cyclic di-GMP or cyclic dinucleotides thereof can be used to inhibit cancer cell proliferation or to increase cancer cell apoptosis in vitro as well as in vivo in a patient.

The invention relates to an application of antagonizing and / or blocking IL-6 / IL-6R / gp130 signaling pathway in treatment of anti-hepatoma, and specifically relates to an application of an antagonist and / or a blocking agent of the IL-6 / IL-6R / gp130 signaling pathway and conventional liver cancer treatment drugs (such as cisplatin, doxorubicin and sorafenib) in preparation of anti-hepatoma drug compositions. The composition provided by the invention has significant curative effect for the liver cancers and has the advantages of small toxic and side effects, capability for synergizing with the conventional liver cancer treatment drugs and increasing the effect of the conventional anti-hepatoma treatment, and the like.

The invention provides five-alga probiotic enzyme tablets and a preparation method thereof. The five-alga probiotic enzyme tablets are prepared from the following raw materials in parts by mass: 10-20 parts of chlorella vulgaris, 1-10 parts of dunaliella salina, 1-10 parts of euglena, 1-10 parts of red algae, 10-20 parts of spirulina and 10-20 parts of probiotic powder. The five-alga probiotic enzyme tablets provided by the invention adopt the chlorella, dunaliella salina, red algae, spirulina and euglena for complementation in nutrition, and obtain trace elements easier to absorb by a human body through probiotic fermentation, thereby helping to reinforce the immunologic function of the human body, resist virus infection and proliferation, inhibit cancer cell proliferation, repair the damage of an organism quickly, remove vivotoxin, suppress blood pressure and blood sugar rise, reduce the serum cholesterol content, and thus improve the comprehensive conditioning of the human body.

The invention discloses a human SFRP1 gene sequence and coding protein and application in the drug to inhibit tumour from growing, which is characterized by the following: treating or lessening the loss, non-functional or abnormal disease of human SFRP1 protein; making human SFRP2 gene express in the cancer cell through gene-transmitting technology or supplementing human SFRP1 protein in vitro; controlling cancer from breeding and killing cancer cell.

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R1, R2, R2′, R3, R4, R5, R6, R7, R8, R9 are as described herein.

The present invention relates to novel compounds having a phosphatidylinositol 3 kinase (PI3K) inhibiting activity which are useful as medicaments, more particularly as antitumor agent. Novel 3-(imidazoÄ1,2-aÜpyridin-3-yl) derivatives or salts thereof exhibit an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity, and are thus useful as medicaments, especially as PI3K inhibitors and antitumor agents.

The invention discloses a nitric oxide (NO) donor-type farnesyl thiosalicylic acid (FTA) derivative, and pharmaceutically acceptable salt, a preparation method and medical application thereof. The FTA derivative is a compound obtained by carrying out heterozygosis on a NO donor furazan nitrogen oxide and Ras protein inhibitor FTA by an ester bond or an amido bond. Pharmacological test results show that the FTA derivative can reserve the Ras protein inhibiting activity of FTA and simultaneously releases high-concertration NO to induce cancer cell apoptosis and enhance the inhibiting action on cancer cell proliferation; compared with the FTA, the FTA derivative has more excellent anti-tumor activity, and therefore, the compound can be suitable for treating various clinical malignant tumours.

The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation.

The invention relates to application of LCE3E to diagnosis and treatment of an oral cancer. According to the application, transcriptome deep sequencing analysis is performed through a high-throughput sequencing platform to preliminarily screen out LCE3E genes obvious in differential expression in oral squamous cell carcinoma tissue and normal tissue, a further RT-PCR experiment proves high expression of the LCE3E genes in the oral squamous cell carcinoma tissue, and an siRNA interference experiment shows that interference to expression of the LCE3E genes can effectively suppress proliferation of oral cancer cells. Oral cancer molecular markers in the application have significant clinical practical application value.

The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Compositions of matter are described which contain restricted cancer cells. When so restricted, the cells produce an unexpectedly high amount of material which suppresses cancer cell proliferation. The phenomenon crosses cancer type and species lines. Processes for making these compositions, and their use, are also described.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.

The invention provides novel application of 4-hydroxy salicylamide in the field of pharmacy. The compound is an inhibitor of ribonucleotide reductase (RR), and can achieve the aims of inhibiting replication of HBV and treating hepatitis, in particular the hepatitis B by inhibiting activity of RR enzyme to block synthesis of dNTPs (deoxynucleotide triphosphates) required by hepatitis B virus (HBV)replication, achieve the aim of preventing and treating liver cancer by inhibiting the activity of RR of liver cancer cells, including the RR activity activated by HBV to inhibit proliferation of liver cancer cells, and achieve the aim of treating various tumors by inhibiting the RR. The 4-hydroxy salicylamide can be used for preventing and treating hepatitis B, liver cancer, oropharyngeal epithelioma, colorectal cancer, ovarian cancer, non-small cell lung cancer, chronic myeloid leukemia and other tumors, and has important application prospect.

The invention belongs to the technical field of tea production, and particularly relates to a Tetrastigma hemsleyanum Duels et Gilg tea with high contents of Tetrastigma hemsleyanum Duels et Gilg flavone, polysaccharide and kaempferol, and a manufacturing method of the Tetrastigma hemsleyanum Duels et Gilg tea. The method comprises the following steps: (1), spreading fresh Tetrastigma hemsleyanumDuels et Gilg leaves for 10-20 minutes; (2), fixation: deactivating enzymes of the Tetrastigma hemsleyanum Duels et Gilg leaves by adopting a microwave tea fixation drier; (3), flat pressing for shaping: uniformly spreading the Tetrastigma hemsleyanum Duels et Gilg leaves subjected to fixation on a bamboo skin board, and pressing another bamboo skin board on the leaves to enable the cooled Tetrastigma hemsleyanum Duels et Gilg leaves to be shaped; and (4), drying: drying the semi-finished products processed in the step (2) by a microwave tea machine. The Tetrastigma hemsleyanum Duels et Gilg tea is natural green, is bright green in color and light green in grounds, does not contain caffeine, is rich in Tetrastigma hemsleyanum Duels et Gilg flavone, polysaccharide, kaempferol and other ingratiates, can effectively inhibit cancer cell proliferation, promotes cancer cell poptosis, has no toxic or side effects and is easy to absorb and beneficial to health. The Tetrastigma hemsleyanum Duels et Gilg leaves are tender, have less fibers, and can be eaten after being brewed.